Henry Schein (NASDAQ:HSIC) Director Kurt Kuehn Sells 2,844 Shares

Henry Schein, Inc. (NASDAQ:HSIC) Director Kurt Kuehn sold 2,844 shares of the business’s stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $78.96, for a total transaction of $224,562.24. Following the transaction, the director owned 15,420 shares in the company, valued at approximately $1,217,563.20. This trade represents a 15.57% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Henry Schein Stock Up 0.3%

NASDAQ:HSIC traded up $0.21 on Wednesday, hitting $76.50. The stock had a trading volume of 1,060,248 shares, compared to its average volume of 1,429,446. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.76 and a current ratio of 1.38. The stock has a market cap of $8.77 billion, a P/E ratio of 23.39, a price-to-earnings-growth ratio of 2.31 and a beta of 0.88. Henry Schein, Inc. has a 1 year low of $60.56 and a 1 year high of $89.29. The firm’s fifty day simple moving average is $78.23 and its two-hundred day simple moving average is $72.74.

Henry Schein (NASDAQ:HSIC) last posted its earnings results on Tuesday, February 24th. The company reported $1.34 EPS for the quarter, topping the consensus estimate of $1.30 by $0.04. Henry Schein had a net margin of 3.02% and a return on equity of 15.16%. The firm had revenue of $3.44 billion for the quarter, compared to analysts’ expectations of $3.34 billion. The company’s quarterly revenue was up 7.7% compared to the same quarter last year. During the same quarter last year, the firm earned $1.19 EPS. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Analysts predict that Henry Schein, Inc. will post 4.74 earnings per share for the current year.

Hedge Funds Weigh In On Henry Schein

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HSIC. Ameriprise Financial Inc. increased its stake in shares of Henry Schein by 3,275.2% in the second quarter. Ameriprise Financial Inc. now owns 2,266,858 shares of the company’s stock worth $165,594,000 after purchasing an additional 2,199,695 shares in the last quarter. Bank of Montreal Can lifted its stake in shares of Henry Schein by 3,655.7% during the 4th quarter. Bank of Montreal Can now owns 2,144,773 shares of the company’s stock valued at $162,102,000 after buying an additional 2,087,666 shares in the last quarter. Norges Bank bought a new position in Henry Schein in the 2nd quarter worth approximately $89,476,000. M.D. Sass LLC bought a new position in Henry Schein in the 2nd quarter worth approximately $79,201,000. Finally, Schroder Investment Management Group grew its stake in Henry Schein by 149.3% in the 2nd quarter. Schroder Investment Management Group now owns 1,563,899 shares of the company’s stock valued at $114,243,000 after buying an additional 936,471 shares in the last quarter. Institutional investors own 96.62% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. JPMorgan Chase & Co. upped their price objective on Henry Schein from $78.00 to $92.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. UBS Group lifted their target price on Henry Schein from $79.00 to $87.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 25th. Wall Street Zen raised shares of Henry Schein from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 28th. Barclays started coverage on shares of Henry Schein in a report on Monday, December 8th. They set an “overweight” rating and a $86.00 price objective for the company. Finally, Leerink Partners reaffirmed a “market perform” rating on shares of Henry Schein in a research report on Monday. Six research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Henry Schein has an average rating of “Hold” and an average target price of $85.58.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.